Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation

Osimertinib is a standard therapy for the treatment of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor gene (EGFR) mutations, but most patients with EGFR-mutant NSCLC develop secondary resistance to osimertinib. Mesenchymal-epithelial transition gene (MET) alte...

Description complète

Détails bibliographiques

Auteurs principaux:	Shinkichi Takamori, Takashi Seto, Masafumi Yamaguchi, Fumihiko Kinoshita, Takatoshi Fujishita, Kensaku Ito, Ryo Toyozawa, Fumihiro Shoji, Tatsuro Okamoto
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2022-10-01
Collection:	Frontiers in Oncology
Sujets:	lung adenocarcinoma METex14del tepotinib osimertinib resistance
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/fonc.2022.965741/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!